Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders

1. A compound of Formula III:

wherein:

R 1 is C(R 2 )(R 3 )(R 4 );

R 2 is selected from the group consisting of hydrogen, —OH or halogen;

R 3 is selected from the group consisting of hydrogen, —OH, halogen or —CH 3 ;

R 4 is selected from the group consisting of hydrogen, halogen, —CH 3 , phenyl, fluorophenyl, methylphenyl or cyclohexylmethyl;

R 3 and R 4 may join with the carbon to which they are attached to form a cycloalkyl ring, which may be optionally substituted with one or more halogen atoms;

R 6 is —OH;

R 8 is selected from the group consisting of —OH or halogen; and

R 10 is selected from the group consisting of —OH or halogen,

provided that that at least one of R 2 , R 3 , R 4 , R 8 or R 10 comprises a halogen.

2. A compound selected from the group consisting of the following:

or a pharmaceutically acceptable salt, thereof.

3. A kit comprising:

a container having an effective amount of a compound of claim 2 , or a pharmaceutically acceptable salt, or solvate thereof, or any combination of two or more thereof; and

instructions for using the same to treat a degenerative disorder of the central nervous system or a lysosomal storage disorder.

4. A pharmaceutical composition comprising the compound of claim 1 and at least one pharmaceutically acceptable carrier.

5. A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier.